Navellier & Associates’s DexCom DXCM Stock Holding History

Navellier & Associates’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-21,848	Closed	-$1.96M	–	311
2021 Q1	$1.96M	Sell	21,848 -15,304	-41%	-$1.44M	0.35%	93
2020 Q4	$3.43M	Sell	37,152 -23,828	-39%	-$2.13M	0.62%	61
2020 Q3	$6.28M	Sell	60,980 -1,632	-3%	-$171K	1.37%	19
2020 Q2	$6.35M	Sell	62,612 -32	-0.1%	-$2.86K	1.51%	17
2020 Q1	$4.22M	Sell	62,644 -8,472	-12%	-$527K	0.99%	18
2019 Q4	$3.89M	Sell	71,116 -3,008	-4%	-$143K	0.63%	46
2019 Q3	$2.77M	Sell	74,124 -1,456	-2%	-$56.6K	0.46%	58
2019 Q2	$2.83M	Sell	75,580 -1,388	-2%	-$43.6K	0.44%	58
2019 Q1	$2.29M	Sell	76,968 -860	-1%	-$30.2K	0.36%	79
2018 Q4	$2.33M	Buy	+77,828	New	+$2.47M	0.4%	58

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Navellier & Associates's DXCM Position: Q2 2021 in Review

Navellier & Associates sold out of DexCom (DXCM) in Q2 2021, closing a stake of 21,848 shares — an estimated $1.96M sold.

Navellier & Associates first reported a position in DXCM in Q4 2018 and held it in 10 quarters. The position peaked at $6.35M in Q2 2020. 728 funds tracked by Wall St. Rank hold DXCM as of Q2 2021.

Navellier & Associates reported no remaining DexCom position as of Q2 2021 after selling out during the quarter.
Navellier & Associates sold 21,848 DexCom shares in Q2 2021, an estimated $1.96M.
Navellier & Associates first reported a position in DexCom in Q4 2018 and held it in 10 quarters.
Navellier & Associates's DexCom position peaked at $6.35M in Q2 2020.
728 funds tracked by Wall St. Rank held DexCom as of Q2 2021.

Based on Navellier & Associates's 13F filing for Q2 2021, filed 9 Aug 2021.